Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (9969)	1/8/2004 4:23:48 PM
From: nigel bates	Respond to of 52153

Have you tried Julius ? Subject 54064

To: Biomaven who wrote (9969)	1/8/2004 4:26:20 PM
From: Sam Citron	Read Replies (1) \| Respond to of 52153

I'm told Ranbaxy is a gem with imminent ADRs once accounts are US-GAAP compliant.

To: Biomaven who wrote (9969)	1/8/2004 7:17:06 PM
From: Miljenko Zuanic	Respond to of 52153

Two times I had direct contact with India chemists (R&D and manufacturing). To one generic comp we sold process and manufacturing technology for generic compound. My experience is that they are very intelligent, fast to learn and quick to adapt new idea. I do not know how innovative they are, but 3 weeks visit in India was shorten to two weeks due to better than expected pilot-batch runs. 200% opposite story than from China (no offense please). True English school. I think that they are nation that will become leader in generic (PAI), and will be able to move into brand product. Have no opinion about any particular pharma-comp from India. Miljenko